Neuro-Oncology

Jordi Bruna

PRINCIPAL INVESTIGATORS
  • Anna Maria Lucas Calduch
  • Roser Velasco Fargas
  • Carlos Majos Torro
  • Carlos Mesia Barroso
  • Marta Simo Parra
CLINICAL RESEARCHERS
  • Alejandro Fernández Coello
  • Carlos Aguilera Grijalbo
  • Noemi Vidal Sarro
  • Gerard Plans Ahicart
  • Albert Pons Escoda
PREDOCTORAL RESEARCHERS (R1)
  • Aina Calls Cobos
  • Montserrat Alemany Martí
Cancer
Oncobell

Scientific production

24

PAPERS

6 PUBLICATIONS IN FIRST DECILE

12 PUBLICATIONS IN FIRST QUARTILE

Selected publications

  • Cayuela N, Jaramillo-Jiménez E, Càmara E, Majós C, Vidal N, Lucas A, Gil-Gil M, Graus F, Bruna J, Simó M . Cognitive and brain structural changes in long-term oligodendroglial tumor survivors.. NEURO-ONCOLOGY. 10.1093/neuonc/noz130
  • Brandes, AA; Gil-Gil, M; Saran, F; Carpentier, AF; Nowak, AK; Mason, W; Zagonel, V; Dubois, F; Finocchiaro, G; Fountzilas, G; Cernea, DM; Chinot, O; Anghel, R; Ghiringhelli, F; Beauchesne, P; Lombardi, G; Franceschi, E; Makrutzki, M; Mpofu, C; Urban, HJ; Pichler, J. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. ONCOLOGIST. 10.1634/theoncologist.2018-0290
  • Izquierdo C, Barritault M, Poncet D, Cartalat S, Joubert B, Bruna J, Jouanneau E, Guyotat J, Vasiljevic A, Fenouil T, Berthezène Y, Honnorat J, Meyronet D, Ducray F . Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.. NEUROSURGERY. 10.1093/neuros/nyy513
  • Castet F., Alanya E., Vidal N., Izquierdo C., Mesia C., Ducray F., Gil-Gil M., Bruna J.. Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. JOURNAL OF NEURO-ONCOLOGY. 10.1007/s11060-019-03183-2
  • Janin M., Ortiz-Barahona V., de Moura M.C., Martínez-Cardús A., Llinàs-Arias P., [45 authors], Blanco S., Seoane J., Preiss T., Pandolfi P.P., Esteller M.. Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. ACTA NEUROPATHOLOGICA. 10.1007/s00401-019-02062-4

Research highlights

PROJECTS

4 Ongoing projects
3 Started project

 

21 Ongoing clinical trials
9 Started clinical trials

PUBLISHED WORKS

1 Thesis

2 Clinical guidelines

Selected projects

  • Estudi exploratori sobre la etiopatogènia, biomarcadors de risc i mecanismes implicats en la regeneració de la neuropatia induïda per platins (18/7/2019 – 31/12/2021) PI: BRUNA ESCUER, JORDI. Funder: DEPARTAMENT SALUT (PR).
  • Cáncer de pulmón y toxicidad cognitiva: marcadores serológicos y de neuroimagen de disrupción de la barrera hemato-encefálica (1/1/2019 – 31/12/2021) PI: SIMO PARRA, MARTA. Funder: FIS-Instituto de Salud Carlos III.
  • Mapear la memoria: Mejora del diagnóstico de la reserva funcional hipocámpica en pacientes con epilepsia farmacoresistente (1/7/2019 – 30/6/2022) PI: FERNANDEZ COELLO, ALEJANDRO. Funder: HOSPITAL UNIVERSITARI DE BELLVITGE.
  • A phase III trial of Marizomib in combination with standard Temozolomide-based radiochemotherapy versus standard Temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma (25/9/2019
    – ) PI: BRUNA ESCUER, JORDI. Funder ref.: 1709-BTG (EORTC).
  • A multicenter randomized phase II trial on intraoperative radiotherapy in newly diagnosed glioblastoma multiforme (INTRAGO II) NCT02685605 (6/2/2018 – 6/2/2022) PI: LUCAS CALDUCH, ANA. Funder ref.: INTRAGO II.
  • Radiation versus observation following surgical resection of atypical meningioma: a randomised conrolled trial (HE ROAM TRIAL) (28/1/2019 – ) PI: LUCAS CALDUCH, ANA. Funder ref.: 1308-ROG.
  • A phase 3, double-blind, multicenter, placebo-controlled study of Pledox used on top of modified Folfox6 (5-FU/FA AND Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patients with first-line metastatic colorectal cancer (23/1/2019 – ) PI: VELASCO FARGAS, ROSER. Funder ref.: PP06490.
  • A phase 3, double-blind, multicenter, placebo controlled study of Pledox used on top of modified Folfox6 (5-FU/FA AND Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in the adjuvant treatment of patients with stage iii or high-risk stage ii colorectal cancer (15/2/2019 – 15/2/2023) PI: VELASCO FARGAS, ROSER. Funder ref.: PP06489.